Prime Medicine (PRME) Equity Average (2021 - 2026)

Prime Medicine (PRME) has 6 years of Equity Average data on file, last reported at $98.8 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 24.03% year-over-year to $98.8 million; the trailing twelve-month figure through Mar 2026 stood at $98.8 million (down 24.03% YoY), and the FY2025 full-year result was $137.0 million, down 4.26% from the prior year.
• Equity Average for Q1 2026 stood at $98.8 million, down from $141.3 million in the prior quarter.
• Across five years, Equity Average topped out at $297.5 million in Q1 2023 and bottomed at -$209.1 million in Q3 2022.
• The 5-year median for Equity Average is $141.3 million (2025), against an average of $104.2 million.
• The widest annual swing landed in 2023, when Equity Average soared 284.13%; it then plunged 61.9% in 2025.
• A 5-year view of Equity Average shows it stood at $46.6 million in 2022, then jumped by 250.99% to $163.5 million in 2023, then rose by 4.78% to $171.3 million in 2024, then retreated by 17.5% to $141.3 million in 2025, then plunged by 30.11% to $98.8 million in 2026.
• The last three Equity Average figures came in at $98.8 million (Q1 2026), $141.3 million (Q4 2025), and $111.3 million (Q3 2025), per Business Quant data.

Peer Comparison